Skip to main content

Advertisement

SpringerLink
Log in

CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Pancreatic cancer has the worst prognosis of any gastrointestinal cancer, with the mortality approaching the incidence. Early detection is crucial for improving patient prognosis. We therefore performed a meta-analysis to evaluate and compare the sensitivity and specificity of CA19-9 and CA242 in pancreatic cancer. We searched PubMed, EMBASE, and the Cochrane Library for studies that evaluated the diagnostic validity of CA19-9 and CA242 between January 1966 and March 2011. Meta-analysis methods were used to pool sensitivity and specificity and to construct a summary receiver-operating characteristic (SROC) curve. A total of 11 studies that included 2,316 patients who fulfilled all of the inclusion criteria were considered for analysis. The pooled sensitivities for CA242 and CA19-9 were 0.719 (95 % confidence interval [CI] 0.690–0.746) and 0.803 (95 % CI 0.777–0.826), respectively. The pooled specificities of CA242 and CA19-9 were 0.868 (95 % CI 0.849–0.885) and 0.802 (95 % CI 0.780–0.823), respectively. The diagnostic odds ratio (DOR) estimate was significantly higher for CA242 (16.261) than for CA19-9 (15.637). Our meta-analysis showed that CA242 and CA19-9 could play different roles in the diagnosis of pancreatic cancer. Although the sensitivity of CA242 is lower than that of CA19-9, its specificity is greater.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Maisonneuve P, Lowenfels AB (2010) Epidemiology of pancreatic cancer: an update. Dig Dis 28:645–656

    Article  PubMed  Google Scholar 

  2. Bednar F, Simeone DM (2011) Pancreatic cancer stem cell biology and its therapeutic implications. J Gastroenterol 46(12):1345–1352

    Article  PubMed  Google Scholar 

  3. Chakraborty S, Baine MJ, Sasson AR et al (2011) Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta 1815:44–64

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Tanase CP, Neagu M, Albulescu R et al (2010) Advances in pancreatic cancer detection. Adv Clin Chem 51:145–180

    Article  CAS  PubMed  Google Scholar 

  5. Duffy MJ, Sturgeon C, Lamerz R et al (2010) Tumor markers in pancreatic cancer: a European group on tumor markers (EGTM) status report. Ann Oncol 21:441–447

    Article  CAS  PubMed  Google Scholar 

  6. Lindholm L, Johansson C, Jaiisson EL, Hallberg C, Nilsson O (1985) An inimuno-radiometric assay (IRMA) for the CA 50 antigen. In: Holmgren J (ed) Tumour marker antigen. Studentlitteratur, Lund, pp 123–133

    Google Scholar 

  7. Zamora J, Abraira V, Muriel A et al (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31

    Article  PubMed Central  PubMed  Google Scholar 

  8. Liao Q, Zhao YP, Yang YC et al (2007) Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int 6:641–645

    CAS  PubMed  Google Scholar 

  9. Wu X, Lu XH, Xu T et al (2006) Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin J Dig Dis 7:170–174

    Article  PubMed  Google Scholar 

  10. Ni XG, Bai XF, Mao YL et al (2005) The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 31:164–169

    Article  CAS  PubMed  Google Scholar 

  11. Jiang JT, Wu CP, Deng HF et al (2004) Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. World J Gastroenterol 10:1675–1677

    CAS  PubMed  Google Scholar 

  12. Jiang XT, Tao HQ, Zou SC (2004) Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int 3:464–468

    CAS  PubMed  Google Scholar 

  13. Ozkan H, Kaya M, Cengiz A (2003) Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology 50:1669–1674

    PubMed  Google Scholar 

  14. Banfi G, Bravi S, Ardemagni A et al (1996) CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer. Int J Biol Markers 11:77–81

    CAS  PubMed  Google Scholar 

  15. Haglund C, Lundin J, Kuusela P et al (1994) CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer 70:487–492

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Kawa S, Tokoo M, Hasebe O et al (1994) Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer 70:481–486

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Banfi G, Zerbi A, Pastori S et al (1993) Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem 39:420–423

    CAS  PubMed  Google Scholar 

  18. Röthlin MA, Joller H, Largiadèr F (1993) CA 242 is a new tumor marker for pancreatic cancer. Cancer 71:701–707

    Article  PubMed  Google Scholar 

  19. Winter JM, Yeo CJ, Brody JR (2013) Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 107:15–22

    Article  PubMed  Google Scholar 

  20. Glenn J, Steinberg WM, Kurtzman SH et al (1988) Evaluation of the utility of a radioimmunoassay for serum CA19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 6:462–468

    CAS  PubMed  Google Scholar 

  21. Pleskow DK, Berger HJ, Gyves J et al (1989) Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 110:704–709

    Article  CAS  PubMed  Google Scholar 

  22. Bauer TM, El-Rayes BF, Li X (2013) Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy. Cancer 119:285–292

    Article  CAS  PubMed  Google Scholar 

  23. Abdel-Misih SR, Hatzaras I, Schmidt C et al (2011) Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease. Ann Surg Oncol 18:1116–1121

    Article  PubMed Central  PubMed  Google Scholar 

  24. Buxbaum JL, Eloubeidi MA (2010) Molecular and clinical markers of pancreas cancer. JOP 11:536–544

    PubMed  Google Scholar 

  25. Goggins M (2005) Molecular markers of early pancreatic cancer. J Clin Oncol 23:4524–4531

    Article  CAS  PubMed  Google Scholar 

  26. Zhang LZ, Gong YF, Tu ZX (2002) Quantitative determination of serum levels of CA242 in patients with pancreatic cancer and its significance. Chin J Pancreatol 2:20–21

    Google Scholar 

  27. Gemmel C, Eickhoff A, Helmstädter L, Riemann JF (2009) Pancreatic cancer screening: state of the art. Expert Rev Gastroenterol Hepatol 3:89–96

    Article  CAS  PubMed  Google Scholar 

  28. D’Onofrio M, Gallotti A, Pozzi Mucelli R (2010) Imaging techniques in pancreatic tumors. Expert Rev Med Devices 7:257–273

    Article  PubMed  Google Scholar 

  29. Grote T, Logsdon CD (2007) Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol 23:508–514

    Article  CAS  PubMed  Google Scholar 

  30. Mendieta Zerón H, García Flores JR, Romero Prieto M (2009) Limitations in improving detection of pancreatic adenocarcinoma. Future Oncol 5:657–668

    Article  PubMed  Google Scholar 

  31. Chakraborty S, Baine MJ, Sasson AR, Batra SK (2011) Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta 1815:44–64

    CAS  PubMed Central  PubMed  Google Scholar 

  32. Bünger S, Laubert T, Roblick UJ, Habermann JK (2011) Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol 137:375–389

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Rd., Shanghai, 200040, People’s Republic of China

    Ji-Cong Gui & Xing-Dang Liu

  2. Pudong Institute for Health Development, 818 Laiyang Rd., Pudong, Shanghai, 200129, People’s Republic of China

    Wei-Li Yan

Authors
  1. Ji-Cong Gui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei-Li Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xing-Dang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xing-Dang Liu.

Additional information

Ji-Cong Gui and Wei-Li Yan contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gui, JC., Yan, WL. & Liu, XD. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis. Clin Exp Med 14, 225–233 (2014). https://doi.org/10.1007/s10238-013-0234-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-013-0234-9

Keywords

Search

Navigation